Taisho Signs an Exclusive License Agreement with Moberg Pharma to Develop and Commercialize MOB-015 in Japan

 Taisho Signs an Exclusive License Agreement with Moberg Pharma to Develop and Commercialize MOB-015 in Japan

Taisho Signs an Exclusive License Agreement with Moberg Pharma to Develop & Commercialize MOB-015 in Japan

Shots:

  • Moberg to receive $5M up front, $50M as development, regulatory & commercial milestone along with supply fees & royalties on sales. Taisho to get exclusive right to develop, register & commercialize MOB-015 in Japan and will fund & conduct development and registration activities in Japan
  • The agreement is the third major agreement for MOB-015, validating the market potential of the therapy to treat onychomycosis
  • MOB-015 is a topical formulation of Moberg’s terbinafine, being evaluated in P-III study in 800+ patients across North America & EU for 52wks. with 1EPs as complete cure of target nail with its anticipated results in Dec’2019 & Q2’2020 respectively

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post